Nurix Therapeutics Statistics
Share Statistics
Nurix Therapeutics has 70.84M shares outstanding. The number of shares has increased by 32.8% in one year.
| Shares Outstanding | 70.84M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 68.89M |
| Failed to Deliver (FTD) Shares | 3.34K |
| FTD / Avg. Volume | 0.37% |
Short Selling Information
The latest short interest is 9.46M, so 13.35% of the outstanding shares have been sold short.
| Short Interest | 9.46M |
| Short % of Shares Out | 13.35% |
| Short % of Float | 13.73% |
| Short Ratio (days to cover) | 11.33 |
Valuation Ratios
The PE ratio is -2.35 and the forward PE ratio is -9.72.
| PE Ratio | -2.35 |
| Forward PE | -9.72 |
| PS Ratio | 4.39 |
| Forward PS | 22 |
| PB Ratio | 1.69 |
| P/FCF Ratio | -3.77 |
| PEG Ratio | n/a |
Enterprise Valuation
Nurix Therapeutics Inc. has an Enterprise Value (EV) of 313.97M.
| EV / Earnings | -2.18 |
| EV / Sales | 4.08 |
| EV / EBITDA | -2.22 |
| EV / EBIT | -2.02 |
| EV / FCF | -3.5 |
Financial Position
The company has a current ratio of 3.4, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.4 |
| Quick Ratio | 3.4 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 3.1 |
| Cash Flow / Debt | -12.68 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.72% and return on capital (ROIC) is -67.1%.
| Return on Equity (ROE) | -0.72% |
| Return on Assets (ROA) | -0.4% |
| Return on Capital (ROIC) | -67.1% |
| Revenue Per Employee | 271.08K |
| Profits Per Employee | -506.86K |
| Employee Count | 284 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 122.58% in the last 52 weeks. The beta is 2.2, so Nurix Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.2 |
| 52-Week Price Change | 122.58% |
| 50-Day Moving Average | 23.69 |
| 200-Day Moving Average | 19.74 |
| Relative Strength Index (RSI) | 40.11 |
| Average Volume (20 Days) | 909.98K |
Income Statement
In the last 12 months, Nurix Therapeutics had revenue of $76.99M and earned -$143.95M in profits. Earnings per share was $-2.65.
| Revenue | 76.99M |
| Gross Profit | -112.16M |
| Operating Income | -155.06M |
| Net Income | -143.95M |
| EBITDA | -141.41M |
| EBIT | -155.06M |
| Earnings Per Share (EPS) | -2.65 |
Balance Sheet
The company has $54.63M in cash and $30.61M in debt, giving a net cash position of $24.01M.
| Cash & Cash Equivalents | 54.63M |
| Total Debt | 30.61M |
| Net Cash | 24.01M |
| Retained Earnings | -545.20M |
| Total Assets | 513.60M |
| Working Capital | 369.75M |
Cash Flow
In the last 12 months, operating cash flow was -$81.36M and capital expenditures -$8.40M, giving a free cash flow of -$89.77M.
| Operating Cash Flow | -81.36M |
| Capital Expenditures | -8.40M |
| Free Cash Flow | -89.77M |
| FCF Per Share | -1.65 |
Margins
Gross margin is -145.69%, with operating and profit margins of -201.41% and -186.98%.
| Gross Margin | -145.69% |
| Operating Margin | -201.41% |
| Pretax Margin | -186.98% |
| Profit Margin | -186.98% |
| EBITDA Margin | -183.68% |
| EBIT Margin | -201.41% |
| FCF Margin | -116.6% |
Dividends & Yields
NRIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.11% |
| FCF Yield | -6.27% |
Analyst Forecast
The average price target for NRIX is $32.5, which is 60.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.5 |
| Price Target Difference | 60.8% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
Scores
| Altman Z-Score | 4.27 |
| Piotroski F-Score | 3 |